Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Replay: Pembrolizumab Re-challenge in Advanced NSCLC
NCT03526887Phase 2Completed
- Sponsor
- Fundación GECP
- Start
- Jul 2018
- Primary completion
- Dec 2022
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of pembrolizumab in non-small cell lung cancer (NSCLC) (2 cohorts), sponsored by Fundación GECP. Primary endpoint: Overall Survival at 48 months. Started Jul 2018; status: completed.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03526887.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03526887.